Browse the evidence

Effect sizes of GLP-1 receptor agonists in schizophrenia are mostly smaller than in the general population.

While GLP-1 receptor agonists can aid in weight loss, practitioners should manage expectations regarding the magnitude of effect in this population.

Future trials of GLP-1 receptor agonists could focus on dual or triple agonist agents.

Exploring dual or triple agonist therapies may enhance treatment options for weight management in schizophrenia.

The SLOW group reported a higher rating of perceived exertion (RPE) than the FAST group.

Strength and conditioning professionals should consider RPE when designing training programs with different tempos.

A semisupervised high-intensity interval training (HIT) intervention did not increase menstrual frequency in women with PCOS after 12 months.

Practitioners should note that HIT may not improve menstrual frequency in women with PCOS.

Protein supplementation does not significantly augment the effects of resistance exercise training on muscle mass or strength in older adults (≥70 years) compared to resistance exercise alone.

If you are over 70 and doing resistance training, you do not need to buy protein supplements to get better results. The research shows that getting protein from food is just as effective as supplements for building muscle and strength in this age group. Focus on eating enough protein overall rather than spending money on powders.

Preoperative insulin therapy and T2DM duration ≥5 years were predictors of less favorable outcomes.

Consideration of insulin therapy and diabetes duration is crucial for predicting surgical outcomes.

MYOD1, MYF5, and MYF6 mean methylation was reduced after 4 and 8 hours in response to all exercise protocols.

Resistance, high-intensity interval, and concurrent exercise can effectively reduce DNA methylation in myogenic regulatory factors.

Changes in DNA methylation and mRNA expression were largely confined to the late (4-8 h) recovery period.

Recovery periods after exercise are critical for observing changes in muscle regulatory factors.

Lesser known factors such as cerebral blood flow, food cue reactivity, gut hormone levels, and dietary adherence possibly impact variability of response to liraglutide.

Healthcare providers should consider these lesser-known factors when evaluating patient responses to liraglutide.

Ten proteins were associated with different rates of weight regain, some specifying pathways of chemotaxis and innate immune responses.

Identifying specific proteins may help tailor interventions for weight regain.

24% of patients with diabetes and delayed gastric emptying were on a GLP-1 receptor agonist.

Practitioners should be aware that a notable percentage of diabetic patients with delayed gastric emptying are using GLP-1R agonists.

GLP-1 receptor agonists use was associated with delayed gastric emptying in patients with diabetes for less than 10 years.

Clinicians should consider the duration of diabetes when prescribing GLP-1R agonists.

The study could not establish statistical significance regarding the likelihood of delayed gastric emptying in patients on GLP-1R agonists.

Further research is needed to clarify the relationship between GLP-1R agonists and gastric emptying.

High-circulating lipid availability results in lower peak aminoacidemia following protein ingestion.

Understanding the impact of lipid levels on amino acid availability can inform dietary strategies.

Semaglutide has a higher pooled reporting odds ratio (ROR) for gastrointestinal adverse drug reactions (GADRs) compared to liraglutide (5.53 vs 3.95).

Clinicians should consider the higher gastrointestinal risk associated with semaglutide when prescribing.

Semaglutide has a later pooled time-to-onset median of GADRs compared to liraglutide (7 days vs 4 days).

Healthcare providers should be aware of the delayed onset of gastrointestinal issues with semaglutide.

Recommendations for incorporating genetics and genomics into clinical decision-making for behavioral weight loss are outlined.

Practitioners can consider these recommendations to enhance behavioral weight loss interventions.

Naltrexone/bupropion increased proglucagon levels and decreased GLP-2, glucagon, and the major proglucagon fragment.

Naltrexone/bupropion may be beneficial for altering specific hormone levels related to metabolism.

Gastric bypass surgery has positive effects that cannot be solely explained by caloric restriction.

Practitioners should consider factors beyond caloric intake when evaluating gastric bypass outcomes.

Gut-derived signals significantly modulate outcomes after bariatric surgery.

Understanding gut-derived signals can help in developing interventions for obesity.

High responders to hypertrophic strength training showed a decrease of -10.5% in vastus lateralis cross-sectional area (VLCSA) during detraining.

Practitioners should be aware that high responders may experience significant muscle loss during periods of detraining.

DEPTOR is identified as a critical mechanistic candidate for disuse-driven MPS suppression.

Targeting DEPTOR may offer a therapeutic approach to counteract muscle loss during periods of disuse.

Lifestyle interventions and older antiobesity pharmacotherapies have been associated with less than 12% body weight reduction and no clear benefit to reduce MACE risk.

Practitioners should be aware that traditional weight loss methods may not significantly reduce cardiovascular risks.

Retatrutide increased heart rate by up to 6.7 beats/min, which may offset some benefits of weight loss.

Weight loss treatments like retatrutide may have cardiovascular implications that need to be considered.